These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20512572)

  • 1. [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
    Krause BJ; Souvatzoglou M; Herrmann K; Weber AW; Schuster T; Buck AK; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler SI; Senekowitsch-Schmidtke R; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1861-8. PubMed ID: 20512572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
    Schwarzenböck S; Sachs D; Souvatzoglou M; Schuster T; Nawroth R; Weirich G; Treiber U; Wester HJ; Ziegler S; Schwaiger M; Senekowitsch-Schmidtke R; Krause BJ
    Nuklearmedizin; 2013; 52(4):141-7. PubMed ID: 23396481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
    Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
    Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.
    Schwarzenböck SM; Gertz J; Souvatzoglou M; Kurth J; Sachs D; Nawroth R; Treiber U; Schuster T; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Henriksen G; Wester HJ; Krause BJ
    Mol Imaging Biol; 2015 Apr; 17(2):248-56. PubMed ID: 25163420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
    Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
    J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
    Ceci F; Castellucci P; Graziani T; Schiavina R; Renzi R; Borghesi M; Di Tullio P; Brunocilla E; Ardizzoni A; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):84-91. PubMed ID: 26323576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early response assessment in prostate carcinoma by ¹⁸F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models.
    Oyama N; Hasegawa Y; Kiyono Y; Kobayashi M; Fujibayashi Y; Ponde DE; Dence C; Welch MJ; Yokoyama O
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):81-9. PubMed ID: 20878403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [11C]Choline as a PET biomarker for assessment of prostate cancer tumor models.
    Zheng QH; Gardner TA; Raikwar S; Kao C; Stone KL; Martinez TD; Mock BH; Fei X; Wang JQ; Hutchins GD
    Bioorg Med Chem; 2004 Jun; 12(11):2887-93. PubMed ID: 15142549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.
    Müller SA; Holzapfel K; Seidl C; Treiber U; Krause BJ; Senekowitsch-Schmidtke R
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1434-42. PubMed ID: 19352653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of [
    Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the potential of [11C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer.
    Challapalli A; Barwick T; Tomasi G; O' Doherty M; Contractor K; Stewart S; Al-Nahhas A; Behan K; Coombes C; Aboagye EO; Mangar S
    Nucl Med Commun; 2014 Jan; 35(1):20-9. PubMed ID: 24201549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [11C]Choline PET/CT in therapy response assessment of a neoadjuvant therapy in locally advanced and high risk prostate cancer before radical prostatectomy.
    Schwarzenböck SM; Knieling A; Souvatzoglou M; Kurth J; Steiger K; Eiber M; Esposito I; Retz M; Kübler H; Gschwend JE; Schwaiger M; Krause BJ; Thalgott M
    Oncotarget; 2016 Sep; 7(39):63747-63757. PubMed ID: 27572317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
    Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tracking Docetaxel-Induced Cellular Proliferation Changes in Prostate Tumor-Bearing Mice with
    Jadvar H; Park R; Vorobyova I; Chen K
    Acad Radiol; 2023 Aug; 30(8):1721-1726. PubMed ID: 36184379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy.
    Giovacchini G; Picchio M; Garcia-Parra R; Briganti A; Abdollah F; Gianolli L; Schindler C; Montorsi F; Messa C; Fazio F
    J Nucl Med; 2014 Feb; 55(2):233-41. PubMed ID: 24408897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
    DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
    Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.
    Sutinen E; Nurmi M; Roivainen A; Varpula M; Tolvanen T; Lehikoinen P; Minn H
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):317-24. PubMed ID: 14628097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of
    Piert M; Shao X; Raffel D; Davenport MS; Montgomery J; Kunju LP; Hockley BG; Siddiqui J; Scott PJH; Chinnaiyan AM; Rajendiran T
    J Nucl Med; 2017 Aug; 58(8):1216-1223. PubMed ID: 28302759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
    Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
    BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.